Skip to main content

Table 3 Delphi Study Participant Demographics

From: Methodology in core outcome set (COS) development: the impact of patient interviews and using a 5-point versus a 9-point Delphi rating scale on core outcome selection in a COS development study

  Round 1 Round 2 Round 3
5-point
n = 101
9-point
n = 104
5-point
n = 76
9-point
n = 71
5-point
n = 69
9-point
n = 63
Stakeholder Group n (%)
 Clinician 43 (43%) 48 (46%) 30 (39%) 29 (41%) 27 (39%) 25 (40%)
 Clinician Researcher 23 (23%) 15 (14%) 19 (25%) 14 (20%) 19 (28%) 14 (22%)
 Patient 20 (20%) 22 (21%) 14 (18%) 12 (17%) 10 (14%) 8 (13%)
 Researcher 10 (10%) 13 (13%) 10 (13%) 11 (15%) 10 (14%) 11 (17%)
 Service Provider/Policy Maker 5 (5%) 6 (6%) 3 (4%) 5 (7%) 3 (4%) 5 (8%)
Gender n (%)
 Female 73 (72%) 86 (83%) 57 (75%) 57 (80%) 51 (74%) 50 (79%)
 Male 27 (27%) 18 (17%) 19 (25%) 14 (25%) 18 (26%) 13 (21%)
 Prefer not to say 1 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Age n (%)
 18–24 2 (2%) 1 (1%) 1 (1%) 0 (0%) 1 (1%) 0 (0%)
 25–34 19 (19%) 22 (21%) 16 (21%) 12 (17%) 13 (19%) 9 (14%)
 35–44 34 (34%) 40 (38%) 23 (30%) 28 39%) 20 (29%) 24 (38%)
 45–54 24 (24%) 20 (19%) 19 (25%) 16 (23%) 18 (26%) 15 (24%)
 55–64 18 (18% 15 (14%) 15 (20%) 11 (15%) 15 (22%) 11 (17%)
 65+ 4 (4%) 6 (6%) 2 (3%) 4 (6%) 2 (3%) 4 (6%)
Country n (%)
 Argentina 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
 Australia 4 (4%) 4 (4%) 3 (4%) 3 (4%) 3 (4%) 3 (5%)
 Austria 1 (1%) 0 (0%) 1 (1%) 0 (0%) 1 (1%) 0 (0%)
 Belgium 3 (3%) 1 (1%) 3 (4%) 1 (1%) 3 (4%) 1 (2%)
 Brazil 1 (1%) 0 (0%) 1 (1%) 0 (0%) 1 (1%) 0 (0%)
 Canada 6 (6%) 11 (11%) 4 (5%) 9 (13%) 4 (6%) 9 (14%)
 Colombia 1 (1%) 0 (0%) 1 (1%) 0 (0%) 1 (1%) 0 (0%)
 Cook Islands 0 (0%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
 Croatia 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
 Denmark 1 (1%) 2 (2%) 1 (1%) 2 (3%) 1 (1%) 2 (3%)
 Egypt 0 (0%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
 Finland 1 (1%) 0 (0%) 1 (1%) 0 (0%) 1 (1%) 0 (0%)
 Germany 1 (1%) 0 (0%) 1 (1%) 0 (0%) 1 (1%) 0 (0%)
 Iceland 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
 Iran 0 (0%) 2 (2%) 0 (0%) 2 (3%) 0 (0%) 2 (3%)
 Ireland 26 (26%) 19 (18%) 18 (24%) 13 (18%) 14 (20%) 10 (16%)
 Israel 1 (1%) 0 (0%) 1 (1%) 0 (0%) 1 (1%) 0 (0%)
 Malaysia 4 (4%) 0 (0%) 2 (3%) 0 (0%) 2 (3%) 0 (0%)
 Mexico 0 (0%) 3 (3%) 0 (0%) 3 (4%) 0 (0%) 2 (3%)
 Nepal 2 (2%) 0 (0%) 2 (3%) 0 (0%) 2 (3%) 0 (0%)
 Netherlands 3 (3%) 1 (1%) 3 (4%) 1 (1%) 3 (4%) 1 (2%)
 New Zealand 1 (1%) 2 (2%) 1 (1%) 1 (1%) 1 (1%) 1 (2%)
 Norway 7 (7%) 7 (7%) 7 (9%) 4 (6%) 7 (10%) 4 (6%)
 Philippines 0 (0%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
 Poland 0 (0%) 1 (1%) 0 (0%) 1 (1%) 0 (0%) 1 (2%)
 Portugal 1 (1%) 2 (2%) 1 (1%) 1 (1%) 1 (1%) 1 (2%)
 South Africa 0 (0%) 1 (1%) 0 (0%) 1 (1%) 0 (0%) 1 (2%)
 Sweden 11 (11%) 15 (14%) 9 (12%) 9 (13%) 9 (13%) 9 (14%)
 Switzerland 1 (1%) 3 (3%) 1 (1%) 3 (4%) 0 (0%) 3 (5%)
 UK 11 (11%) 17 (16%) 8 (11%) 9 (13%) 7 (10%) 5 (8%)
 USA 11 (11%) 9 (9%) 7 (9%) 7 (10%) 6 (9%) 7 (11%)
 Zimbabwe 0 (0%) 1 (1%) 0 (0%) 1 (1%) 0 (0%) 1 (2%)